Arrivobio

1 known investors

Arrivo BioVentures is a holding company that provides management oversight and funding for its subsidiaries, Sirtsei Pharmaceuticals and Panafina. The subsidiaries develop drug candidates including Forvisirvat (SP-624) for major depressive disorder and RABI-767 for severe acute pancreatitis.

Biotech